147,498 Shares in Certara, Inc. (NASDAQ:CERT) Bought by abrdn plc

abrdn plc acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT – Get Rating) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 147,498 shares of the company’s stock, valued at approximately $2,370,000. abrdn plc owned 0.09% of Certara at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC acquired a new position in Certara during the 3rd quarter worth approximately $95,000. Captrust Financial Advisors grew its position in Certara by 135.8% in the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock valued at $99,000 after purchasing an additional 2,665 shares during the period. MetLife Investment Management LLC bought a new stake in Certara during the 1st quarter valued at $111,000. PNC Financial Services Group Inc. raised its holdings in Certara by 18.3% during the first quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock worth $126,000 after buying an additional 905 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Certara in the third quarter valued at $135,000. Institutional investors own 75.45% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on CERT. Stephens initiated coverage on shares of Certara in a report on Tuesday, April 11th. They issued an “overweight” rating and a $28.00 target price on the stock. Morgan Stanley upped their price target on Certara from $20.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, March 10th. Credit Suisse Group raised their price objective on shares of Certara from $22.00 to $27.00 in a report on Monday, March 27th. Barclays downgraded shares of Certara from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $21.00 to $25.00 in a report on Monday, April 3rd. Finally, TheStreet raised shares of Certara from a “d+” rating to a “c” rating in a report on Monday, April 10th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Certara Price Performance

NASDAQ CERT opened at $21.01 on Wednesday. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of 233.44, a PEG ratio of 1.15 and a beta of 1.57. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.71 and a quick ratio of 3.71. Certara, Inc. has a 1-year low of $10.60 and a 1-year high of $24.96. The business’s fifty day moving average price is $22.89 and its 200-day moving average price is $19.43.

Certara (NASDAQ:CERT – Get Rating) last released its quarterly earnings results on Monday, May 8th. The company reported $0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $91.29 million. Certara had a return on equity of 5.53% and a net margin of 4.03%. Certara’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. On average, equities analysts predict that Certara, Inc. will post 0.37 earnings per share for the current year.

Insider Transactions at Certara

In other Certara news, SVP Richard M. Traynor sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, April 14th. The stock was sold at an average price of $23.66, for a total transaction of $118,300.00. Following the sale, the senior vice president now directly owns 182,368 shares in the company, valued at $4,314,826.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

About Certara

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.